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2Abstract
Introduction: Recent advances in electronic nose (e-nose) technology and successful clinical
application are providing new methods for the rapid near-patient diagnosis of disease. There
is real clinical need for new diagnostic tools in otolaryngology.
Materials & Methods: A critical review of recent advances in e-nose technology and current
applications in otolaryngology is presented.
Results: The literature demonstrates evidence of accurate diagnosis in common
otolaryngological conditions such as sinusitis (acute and chronic), chronic suppurative otitis
media, otitis externa and nasal vestibulitis. A significant recent development is the successful
identification of biofilm versus non-biofilm producing Pseudomonas and Staphylococcus
species.
Conclusions: E-nose technology holds significant potential for rapid, non-invasive, point of
care diagnosis of disease in otolaryngology.
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3Introduction
Since the time of the ancient Greeks, physicians have been aware that it is possible to smell
disease on the breath of those afflicted. An obvious example of this is the pear drop like smell
of acetone in the breath of a diabetic. The human nose can be highly trained as an analytical
tool for the discrimination or detection of odours from food (e.g. fish, meat, cheese and wine)
and perfumes (cosmetics, soaps). However, there may be health and safety related issues and
questions regarding inter-observer variability and sensitivity over time.1 To overcome these
difficulties sensor arrays have been used to develop electronic nose (e-nose) technology to
mimic olfactory discrimination based on volatile production patterns.
Since the 1960’s attempts have been made to build an artificial olfactory model to mimic the
olfactory sense of mammals that can detect and discriminate the production of volatile
compounds. Early instruments detected odours using mechanical noses based on redox
reactions moving towards electronic nose technology in the 1980’s. The currently accepted
definition of an electronic nose was proposed by Gardner and Bartlett, in 1994: “An
electronic nose is an instrument which comprises an array of electronic chemical sensors with
partial sensitivity and an appropriate pattern recognition system, capable of recognising
simple or complex odours”.2 The odorant molecules which are interact with the sensor array
surfaces in the electronic nose (and to the olfactory system) are typically hydrophobic and
volatile due to their molecular weight (30-300 Da), strength of the interactions between
molecules and molecular shape.
Volatile organic compounds (VOCs) are organic compounds that can easily become gases or
vapours; as such they can be detected in breath and bodily fluids. Many studies have shown
that for certain pathological conditions such as infection, malignancy, liver and
cardiopulmonary disease, specific patterns of VOCs, so called “volatile fingerprints”, can be
detected. This approach has been used to detect the presence of TB in sputum samples
(Turner and Magan, 2004) and more recently been sued to discriminate between
dermatophytes (Sahgal et al., 2007). Thus, potential exists to utilise this approach for more
accurate diagnosis of disease.
An example of an E-nose device is shown in Figure 1. It mimics the olfactory sense of
mammals. In humans smells are sensed by olfactory sensory neurons in the olfactory
epithelium. Volatile molecules bind to olfactory neuron cell receptors producing a change in
conformation which induces signal transduction to the brain. The active materials of the
sensor array in an electronic nose device (=olfactory receptors) interacts with the VOCs
resulting in a change in the binding surface of each sensor (change in resistance or
conductance) which is transmitted to the pre-processor (olfactory bulb) where the output is
amplified and the noise is reduced. In the final stage the simplified signals (=nerve impulses)
as patterns of responses are processed by the data analysis system (=hypothalamus and
olfactory cortex in the brain). This type of technology can be used as a novel rapid
technology which can be exploited for the diagnosis of diseases and perhaps improve choice
of most appropriate drugs to administer. 3
Otolaryngology has probably the highest number of patients with the commonest range of
symptoms in the field of medicine (otitis externa, rhinorrhea, discharging ears etc). The
electronic nose approach offers many potential benefits to the speciality, because it is non-
invasive, rapid and a relatively portable diagnostic tool. This review will demonstrate that
preliminary applications have already demonstrated successful results and we believe it can
become a substantial tool for the modern ENT department. One area of particular interest is
4the diagnosis of biofilms. Recently two very extensive and interesting reviews have been
published highlighting the importance and correlation of biofilms in Otolaryngology. 4,5
Search Strategy
In order to define the current evidence for the role of e-nose technology in otolaryngology, a
literature review was undertaken. The following electronic databases were searched, Medline
(1952-2009), Embase (1974 -2009), Cinahl(1937 -2009), and the Cochrane Library (1996 -
2009) to source the relevant key texts, references, and reviews. Initially a review of all
applications of e-nose technology was under taken, this was then focused onto clinical
applications. Finally combinations of the following keywords were used: “e-nose”,
“electronic nose”, “infection”, “otolaryngology”, “ENT”, “biofilms” to hone in on
applications relevant to otolaryngology. Four studies, detailed in Table 1, matched our criteria
referring to the use of e-nose in ENT infections and one of them demonstrated the benefit of
the technology e in detecting biofilms. The studies identified are detailed below and the
evidence presented is discussed.
Applications of e-nose technology
Non medical applications
E-nose technology has been widely employed outside of the medical field. Much work has
been done in the food industry on detecting the early microbial spoilage and non-microbial
tainting of food with applications as wide ranging as monitoring the freshness of stored fish6
and meat, to the classification of a wide range of beverages such as coffee, beer, wine.7 There
is significant interest in detecting the levels of mycotoxins produced by fungi in many food
products. Thus, diverse studies have been carried out to differentiate between mycotoxigenic
and non-mycotoxigenic strains of Fusarium, Aspergillus, Penicillium in food raw materials.8,9
Enose technology has also been employed to detect mould growth on books stored in
libraries.10
Clinical applications of e-nose technology
Many pilot studies utilising e-nose technology for the diagnosis of tuberculosis, 11
Helicobacter pylori,12 renal failure,13 urinary tract infection,14 skin fungal infections,15
ventilator acquired pneumonia,16,17 cancer (lung,18,19 breast20), acute asthma21, have been
completed. Each demonstrated promising results of e-nose technology as an adjuvant method
of disease detection, offering the potential for rapid and non-invasive diagnosis currently
unavailable to the clinician.
Table 2 provides further information on the studies highlighted above, detailing samples
analysed and the VOCs used to detect the disease in each of the clinical studies. A number of
reviews of the clinical applications of e-nose technology have been published. 22,23,24
Although wide ranging clinical applications of e-nose technology have been examined in the
literature, only four studies matched our criteria referring to the use of e-nose in ENT
infections and one of these demonstrated the benefit of e-nose technology in detecting
biofilms.
5Otolaryngology and e-nose
Current applications of e-nose technology in otolaryngology
Most recent clinical applications of e-nose technology have been focused on are in the field of
the otolaryngology. Various studies have shown evidence of e-nose effectiveness (high
accuracy) in common otolaryngological conditions such as infection25 and acute and chronic
sinusitis.26,27 Shyknon et. al.25 using a commercial portable electronic nose (Cyranose C320)
recruited 90 patients with various ENT pathologies including otitis externa, chronic
suppurative otitis media and nasal vestibulitis.
Swabs were taken and analysed using the e-nose device before microbiological culture.
Results showed the the e-nose had a sensitivity of 88.2% when compared with the gold
standard of microbiological culture.
Thaler et.al.26 in 2006 showed the potential of this approach by diagnosing bacterial
sinusitis. She used a nasal continuous positive airway mask to sample gas exhaled through the
nose of patients with sinusitis and compared this with controls.
In this study patients were considered infected if there was a positive culture from the swab
sent to microbiology.She was able to predict correctly the diagnosis of sinusitis in at least
72% of samples and to identify infected versus non-infected patients 82% of the time.
Bruno et. al.27 demonstrated the diagnostic usage of the electronic nose studying patients
suffering from chronic rhinosinusitis (CRS). They performed a controlled study dividing the
patients into two groups, the ones suffering with CRS and the healthy ones. The results
showed figures as a high as 85% for the detection of the bacteria in patients with chronic
rhinosinusitis compared to healthy individuals using e-nose technology.
One of the most exciting recent developments was the work done by Thaler et. al. 28 showing
that the e-nose could successfully identify biofilm versus non-biofilm producing bacterial
strains. Their results showed that the e-nose was able to correctly classify biofilm and non-
biofilm producing mutant strains of Pseudomonas and Staphylococcus species with an
accuracy range of 72.2 to 100%”
This has opened a new chapter in the clinical application of e-nose technology, due to recent
data that links biofilms to common antibiotic resistant ear nose and throat infections. Biofilms
are found in cholesteatoma,29, tympanostomy tubes,30 chronic tonsillitis,31 OME,32 speech
valves,33,34. cochlear implantation35,36 and sinusitis.37,38,39,40 A biofilm is a complex
aggregation of microorganisms that have been shown to play a major role in many chronic
antibiotic resistant otolaryngologic infections.41 Biofilms are very difficult to eradicate
because they are enclosed within a matrix that can restrict the diffusion of substances and
bind antimicrobials. This enables effective resistance by biofilm cells against large molecule,
especially anti-microbial proteins such as lysozyme and complement.42 Therefore a non-
invasive method of diagnosing them rapidly in the clinic would be of great benefit and further
investigation is warranted.
6Discussion and Conclusions
E-nose technology has great potential for the diagnosis of diseases due to its rapid detection,
simplicity, non-invasive application and demonstration of high levels of sensitivity in pilot
studies undertaken to date. Potential applications of e-nose technology include
implementation as a diagnostic tool for the identification of patients with particularly virulent
and medically recalcitrant forms of chronic otolaryngologic infections. The recent report
identifying biofilm versus non-biofilm species using e-nose technology is particularly
exciting. The field of Otolaryngology has many potential applications of the technology with
many patients having very common and every day conditions which are difficult to
differentiate in the outpatient setting, but which the e-nose could be used to identify and
enable earlier targeted treatments to be delivered.
The promise of rapid near patient testing enabling identification of causative species thus
facilitating immediate prescription of targeted antibiotics has many advantages. Multi-centre
clinical studies are required to validate the pilot studies undertaken to date and further
evaluate the potential of this exciting technology.
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TABLE I
Clinical applications of enose technology.
Disease / Pathology Sample Volatile Compounds Results Reference
Tuberculosis Sputum hexacosanoic acid 100% correct classification
of Mycobacterium
tuberculosis other related
bacteria
9
Helicobacter pylori Gastric juice 12
Renal failure phenylacetic acid, 13
Urinary Tract Infection Urine Isovaleric acid, alkanes Identification of species of
causative bacteria the
sensitivity and specificity
were 83.5 and 87.6%,
respectively.
14
Skin fungal infections 15
Ventilator acquired pneumonia Breath Nitric oxide Accuracy of at least 80%
comparing e-nose to chest
CT
16,17
Breast cancer Human Breath Alkanes
Monomethylated alkanes
The breath test
distinguished between
women with breast cancer
and healthy volunteers
with a sensitivity of 94.1%
(48/51) and a specificity of
73.8% (31/42) (cross-
validated sensitivity 88.2%
(45/51), specificity 73.8%
(31/42))
20
Lung cancer Human Breath Alkanes
Monomethylated alkanes
For stage 1 lung cancer,
the 22 VOCs had 100%
sensitivity and 81.3%
specificity.Cross-validation
of the combination
correctly predicted the
diagnosis in 71.7% patients
with lung cancer and
66.7% of those without
lung cancer
18,19
Acute asthma Human Breath Pentane Peak expiratory flow rates
were 202+/-29 L/min
during acute asthma and
327+/-26 L/min once acute
asthma subsided (p<0.05).
Exhaled pentane levels
were 8.4+/-2.9 nmol/L
during acute asthma and
decreased significantly to
3.5+/-0.5 nmol/L once
acute asthma subsided
21
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Figure 1: An NST 320 e-nose (Applied Sensors, Sweden) used for clinical studies..
Table II
12
Summary of the four studies investigating the application of E-nose technology to Otolaryngology
Study Publication Year/Journal Patients/specimens included Outcome
Shykhon ME et al 2004/
Journal of Laryngology and
Otology
90 bacterial swabs from 90 patients
with ENT infections
Electronic nose was
correct in 88,2 of cases
comparing with
microbiolgy
Thaler ER et al 2006/
American journal of rhinology
11 patients
Nasal exhalations sampled
72% correct
precidiction of sinusitis
Bruno et al 2008
European archive
Otorhinolaryngology
28 patients ,14 with CRS and 14
healthy
Nasal swabs taken from middle meatus
Accuracy as high as
85% in patients with
CRS
Thaler et al 2008
American journal of rhinology
Biofilm and non biofilm producing
mutant strains of Pseudomonas and
Staphylococcus were incubated and
sampled by e-nose
Electronic nose was
able to indentify biofilm
versus non biofilm with
accurancy ranging from
72 to 100%
